Building better therapeutics with metabolomics
Defining a clearer path from target to drug
Pilot projects will be awarded to two attendees of the webinar
Attrition in pharma/biopharma remains a persistent challenge despite the capacity of technologies to produce more data per sample than ever before. Although volume of data may ultimately provide a benefit in addressing the attrition challenge, data that is tightly and mechanistically coupled to the physiology of disease or drug response represents a "tremendous resource" for providing the most meaningful "line of sight" from the patient to the drug.
Metabolomics (the systematic measurement and interpretation of the biochemicals or “metabolites” within a cell or living system) is a technology that can produce this type of mechanistic data.
In this webcast we describe a recent trend where the use of metabolomics in biopharma R&D is shifting from the pre-clinical space to translational pharmacology and clinical development.
In addition to a brief primer on the fundamentals of metabolomics, we will detail the key reasons that are behind the shift to the clinic including the complexity of human health that the last decade of genomics research has revealed and the recent metabolomic technology advancements that have enabled the comprehensive analysis and interpretation of clinical samples.
In the second part of the presentation, we will describe examples of how investigators are using the technology to enable clinical development – from biomarkers of target engagement, efficacy, and safety through to post-marketing studies. These results highlight how metabolomics has a unique capacity to clarify, with greater confidence, a pathway for clinical development.
- Why metabolomics is a key technology for biopharma R&D
- How groups are using metabolomics in their project work.
- Why there is an increasing trend of using metabolomics in clinical programs.
- How you can engage the platform through a fully funded pilot study.
- How you can be awarded a fully funded pilot project.
Webcast sponsors retain sole responsibility for content
